Galmed Pharmaceuticals GLMD Stock
Galmed Pharmaceuticals Price Chart
Galmed Pharmaceuticals GLMD Financial and Trading Overview
| Galmed Pharmaceuticals stock price | 0.68 USD |
| Previous Close | 0.75 USD |
| Open | 0.7 USD |
| Bid | 0.51 USD x 200 |
| Ask | 0.85 USD x 200 |
| Day's Range | 0.6 - 0.73 USD |
| 52 Week Range | 0.41 - 2.34 USD |
| Volume | 217.73K USD |
| Avg. Volume | 3.01M USD |
| Market Cap | 4.8M USD |
| Beta (5Y Monthly) | 0.618 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GLMD Valuation Measures
| Enterprise Value | -13370013 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7060194 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.3032527 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.587 |
Trading Information
Galmed Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.618 |
| 52-Week Change | -50.87% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 2.34 USD |
| 52 Week Low | 0.41 USD |
| 50-Day Moving Average | 0.62 USD |
| 200-Day Moving Average | 0.95 USD |
GLMD Share Statistics
| Avg. Volume (3 month) | 3.01M USD |
| Avg. Daily Volume (10-Days) | 89.49K USD |
| Shares Outstanding | 6.6M |
| Float | 6.37M |
| Short Ratio | 0.29 |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 2.23% |
| Shares Short | 57.62K |
| Short % of Float | 0.89% |
| Short % of Shares Outstanding | 0.86% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.65% |
| Return on Equity (ttm) | -64.21% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -8427000 USD |
| Net Income Avi to Common (ttm) | -10309000 USD |
| Diluted EPS (ttm) | -2.39 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 18.16M USD |
| Total Cash Per Share (mrq) | 2.76 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 6.547 |
| Book Value Per Share (mrq) | 2.398 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6315000 USD |
| Levered Free Cash Flow (ttm) | -3828125 USD |
Profile of Galmed Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Ramat Gan |
| Address | 16 Abba Hillel Road |
| ZIP | 5250608 |
| Phone | 972 3 693 8448 |
| Website | https://galmedpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3 |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Q&A For Galmed Pharmaceuticals Stock
What is a current GLMD stock price?
Galmed Pharmaceuticals GLMD stock price today per share is 0.68 USD.
How to purchase Galmed Pharmaceuticals stock?
You can buy GLMD shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galmed Pharmaceuticals?
The stock symbol or ticker of Galmed Pharmaceuticals is GLMD.
Which industry does the Galmed Pharmaceuticals company belong to?
The Galmed Pharmaceuticals industry is Biotechnology.
How many shares does Galmed Pharmaceuticals have in circulation?
The max supply of Galmed Pharmaceuticals shares is 6.6M.
What is Galmed Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Galmed Pharmaceuticals PE Ratio is now.
What was Galmed Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Galmed Pharmaceuticals EPS is -2.39 USD over the trailing 12 months.
Which sector does the Galmed Pharmaceuticals company belong to?
The Galmed Pharmaceuticals sector is Healthcare.
Galmed Pharmaceuticals GLMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
- {{ link.label }} {{link}}